newsfilter
← Earnings
Earnings Releases·

MacroGenics — Third Quarter 2026 Earnings Summary

  • Total revenue declined to $18.7 million from $53.0 million in the prior year period, driven by a $50.0 million decrease in milestone revenue, while net loss widened to $20.1 million compared to a $16.8 million net income in the prior year.
  • Cash and marketable securities increased to $287.7 million as of September 30, 2026, following a $119.6 million proceeds from the GMP manufacturing sale and a $24.5 million regulatory milestone payment, supporting a projected cash runway through 2028.
  • The pipeline advanced with Phase 1 dose escalation completion for MGC028, interim Phase 2 results for lorigerlimab, and the first patient dosed for MGC030, with key enrollment and data readouts for MGC026 and MGC028 expected in 2027.
  • Management strengthened the board with two new independent directors and noted a $10.0 million payment from Gilead Sciences, while refining development strategies for MGC026 amidst an evolving competitive landscape.
Company
MACROGENICS INC
Sector
Healthcare
Industry
Biotechnology